| |
| |
| |
|
|
| documents: |
| - id: pharma_001 |
| title: "Prior Authorization and Formulary Pre-Approval" |
| content: > |
| Prior authorization (formulary pre-approval) is a requirement by a payer that a |
| prescriber obtain approval before a specific drug is dispensed and covered. |
| The prescriber submits clinical justification; the payer reviews against formulary |
| criteria and responds within 72 hours for standard requests or 24 hours for urgent cases. |
| Denied requests can be appealed once with additional clinical documentation. |
| tags: [prior-auth, formulary, coverage] |
|
|
| - id: pharma_002 |
| title: "Generic vs Brand Drug Names" |
| content: > |
| Every approved drug has a generic name (the active ingredient, non-proprietary) and |
| one or more brand names assigned by manufacturers. |
| Generic names are used in clinical guidelines and regulatory filings; brand names |
| appear in marketing materials and some payer formularies. |
| Substituting a brand drug with a generic equivalent requires explicit prescriber |
| or payer authorization in some jurisdictions. |
| tags: [drug-name, generic, brand] |
|
|
| - id: pharma_003 |
| title: "Adverse Events and Safety Signals" |
| content: > |
| An adverse event is any undesirable medical occurrence in a patient administered |
| a medicinal product, regardless of causal relationship. |
| A safety signal (pharmacovigilance alert) is a pattern of adverse events that |
| suggests a previously unknown or incompletely documented causal relationship |
| between a drug and an outcome. |
| Adverse events must be reported to the regulatory authority within 15 days for |
| serious unexpected events and 90 days for expected events. |
| tags: [adverse-event, safety, pharmacovigilance] |
|
|
| - id: pharma_004 |
| title: "Drug-Drug Interactions and Contraindications" |
| content: > |
| A drug-drug interaction (contraindication) occurs when one drug affects the activity |
| of another when both are administered together. |
| Interactions range from minor (monitoring recommended) to contraindicated (combination |
| must not be used). Severity classifications follow the clinical pharmacology guidelines |
| maintained in the formulary interaction database. |
| Prescribers are alerted at point-of-care when a contraindicated combination is entered. |
| tags: [drug-interaction, contraindication, safety] |
|
|
| - id: pharma_005 |
| title: "Clinical Guidelines and Prescribing Pathways" |
| content: > |
| A treatment protocol (clinical guideline / prescribing pathway) is an evidence-based |
| document specifying the recommended sequence of therapies for a given condition. |
| Pathways are reviewed annually and updated when new efficacy or safety data emerges. |
| Payers use pathway adherence as a criterion in coverage decisions; deviation requires |
| documented clinical rationale. |
| tags: [protocol, guideline, treatment] |
|
|
| - id: pharma_006 |
| title: "Formulary Coverage Tiers" |
| content: > |
| A formulary is a list of drugs covered by a payer, organized into tiers (benefit tiers) |
| that determine patient cost-sharing. Tier 1 is typically lowest cost (generics); |
| higher tiers carry higher copays. Moving a drug to a higher tier requires |
| a formulary committee review and a minimum 60-day notice to prescribers. |
| tags: [formulary, coverage, tier] |
|
|
| - id: pharma_007 |
| title: "Dosage Adjustment and Titration" |
| content: > |
| A dosage adjustment (dose modification / titration step) is a change to a patient's |
| prescribed dose based on clinical response, tolerability, renal or hepatic function, |
| or drug interaction. Titration schedules specify the starting dose, increment size, |
| and minimum interval between increases. Adjustments outside the approved titration |
| schedule require prescriber documentation and may trigger a prior authorization review. |
| tags: [dosage, titration, dose] |
|
|
| - id: pharma_008 |
| title: "Patient Consent and Enrollment Authorization" |
| content: > |
| Informed consent (enrollment authorization) is the process by which a patient |
| receives and acknowledges sufficient information about a treatment or study |
| to make a voluntary decision. For clinical trials, consent must be obtained |
| before any study procedure. Consent forms are version-controlled; if the |
| protocol changes materially, re-consent is required. |
| tags: [consent, enrollment, patient] |
|
|
| - id: pharma_009 |
| title: "Clinical Trials and Investigational Programs" |
| content: > |
| A clinical trial (investigational program) is a structured study that evaluates |
| the safety or efficacy of a drug, device, or intervention in human subjects. |
| Trials are classified by phase: Phase I tests safety in a small cohort, |
| Phase II assesses efficacy and side effects, Phase III compares against |
| standard treatment at scale. Enrollment eligibility is defined by inclusion |
| and exclusion criteria in the protocol. |
| tags: [clinical-trial, study, investigational] |
|
|
|
|
